P
Predictive Biosciences
Molecular diagnostics company developing diagnostic products for informed cancer management
About Predictive Biosciences
Predictive Biosciences, Inc. is a molecular diagnostics company that develops and provides diagnostic products for cancer management. The company focuses on creating novel molecular diagnostic assays by utilizing its expertise in proteomics, diagnostics, oncology, and tumor biomarkers. Predictive Biosciences has an extensive intellectual property portfolio, which includes 18 issued and pending U.S. patents.
The company's business model is centered around the development and commercialization of these diagnostic tests, which are designed to assist physicians in making informed decisions for cancer treatment and intervention. In addition to its own research and development, Predictive Biosciences has expanded its offerings through acquisitions, such as the purchase of OncoDiagnostic Laboratory, a provider of anatomic pathology laboratory services with a focus on urology.
Predictive Biosciences serves the healthcare market, specifically the oncology and urology sectors. Its clients are primarily physicians and other healthcare providers who use the company's diagnostic tools for cancer diagnosis and monitoring. The company generates revenue through the sale of its diagnostic assays and laboratory services.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- Lexington, United States
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 57.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Predictive Analytics, Biotechnology, Oncology, Non-Invasive medical devices and treatments, Spinout, DT and LS, science-based
- Technology
- Big Data, Deep Tech
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2010
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jan 2013 | $1.3M | $5.2M | Undisclosed | — |
| EARLY VCOther financing | Jul 2012 | $7M | $28M | Undisclosed | — |
Growth signals
Latest recorded traffic for Predictive Biosciences is 0 monthly website visits. Predictive Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Highland Capital Partners
IDG Ventures
Kaiser Permanente Ventures
NEA
Series B and later2 investors entered at this stage
- PIProQuest Investments
Flybridge Capital Partners
Other known investors1 additional known investor
Harvard Medical School
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Predictive Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Predictive Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.